# REFINE (NCT03222609)

> A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03222609
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: AbbVie
- Conditions: Myelofibrosis (MF)
- Interventions: Ruxolitinib; Navitoclax
- Enrollment: 191
- Primary outcome: Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24

## Indexed commentary on REFINE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=refine-nct03222609